Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization-Reference-Cited by-同舟云学术

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

Published:2019-06-06 Issue:11 Volume:4 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Leung Wai-Hang,Gay Joel,Martin Unja,Garrett Tracy E.,Horton Holly M.,Certo Michael T.,Blazar Bruce R.,Morgan Richard A.,Gregory Philip D.,Jarjour Jordan,Astrakhan Alexander

Funder

bluebird bio

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/124430/files/pdf

Reference54 articles.

1. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

2. CAR T cell immunotherapy for human cancer

3. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

4. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

5. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting protein domain modularity to enable synthetic control of engineered cells;Current Opinion in Biomedical Engineering;2024-09

2. Effectors of the Future: Universal Chimeric Antigen Receptor;Transfusion Medicine and Hemotherapy;2024-07-15

3. Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy;BMEMat;2024-06-22

4. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies;Frontiers in Immunology;2024-06-03

5. In vivo manufacture and manipulation of CAR-T cells for better druggability;Cancer and Metastasis Reviews;2024-04-09